title: Eculizumab reverses the potentially fatal effects of kidney graft reperfusion injury.
abstract: Half an hour after reperfusion, the kidney, transplanted to the infant from an adult brain dead standard criteria donor, became flabby and acquired blue color. Hyperacute rejection was suspected as a consequence of false negative cross match, and eculizumab was administered with the purpose to treat antibody-mediated injury, with fast and clear effect. The patient's blood was tested for donor-specific antibodies on the next day, and results were negative. We attribute graft damage to reperfusion injury and explain eculizumab's effectiveness to its ability to prevent progression of reperfusion injury.
authors: Department of Kidney Transplantation, National Research Center for Surgery, Moscow, Russian Federation.
authors: Michael
authors: M
authors: Kaabak
authors: Nadezhda
authors: N
authors: Babenko
authors: Oleg
authors: O
authors: Kuznetsov
authors: Alexander
authors: A
authors: Matveev
authors: Marina
authors: M
authors: Minina
authors: Elena
authors: E
authors: Platova
authors: Margaret
authors: M
authors: Morozova
authors: Tatyana
authors: T
authors: Novozhilova
mesh_terms: D000328:Adult; D000906:Antibodies / Q000737:chemistry; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006084:Graft Rejection; D006801:Humans; D007223:Infant; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D015427:Reperfusion Injury / Q000209:etiology / Q000628:therapy*; D013154:Spleen / Q000473:pathology; D014019:Tissue Donors
chemical_list: D000906:Antibodies; D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab
keywords: antibody induction; hyperacute rejection; kidney transplantation; reperfusion injury